189 results
Page 3 of 10
8-K
EX-99.1
own0e0t
16 Jun 22
Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:35am
8-K
da5f1r3
26 May 22
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
8:35am
8-K
EX-99.1
f341o hi9qx
26 May 22
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
8:35am
8-K
EX-99.1
40biwkwpv0m4cb
12 May 22
Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
8:35am
8-K
908h88qj uv5
10 May 22
Regulation FD Disclosure
8:35am
8-K
EX-99.1
a7gwgdokgzkn2
10 May 22
Regulation FD Disclosure
8:35am
8-K
EX-99.1
5zuvpf5hlaa7ppdhzy0
5 May 22
Regulation FD Disclosure
8:15am
8-K
2qdraiwxezlumbeo7
21 Apr 22
Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma
8:45am
8-K
EX-99.1
dv2t8 ih46mfo0r
21 Apr 22
Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma
8:45am
8-K
EX-99.1
wvadbj 4bnow
25 Mar 22
Moleculin Reports Full Year Financial Results and Provides Programs Update
7:05am
8-K
EX-99.1
z0vtz j4u7holwgtdp
14 Feb 22
Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
9:00am
8-K
72hkqwo kyd
14 Feb 22
Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development
9:00am